市場調査レポート

CINV 既存薬剤&パイプライン薬剤(アロキシ・イメンド・Netupitant-Palonosetron Fdc・Apf530・Rolapitant):世界市場における機会の評価

CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron Fdc, Apf530 & Rolapitant) - Global Market Opportunity Assessment Study, 2012 - 2018

発行 Transparency Market Research 商品コード 256535
出版日 ページ情報 英文 78 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
CINV 既存薬剤&パイプライン薬剤(アロキシ・イメンド・Netupitant-Palonosetron Fdc・Apf530・Rolapitant):世界市場における機会の評価 CINV Existing & Pipeline Drugs (Aloxi, Emend, Netupitant-Palonosetron Fdc, Apf530 & Rolapitant) - Global Market Opportunity Assessment Study, 2012 - 2018
出版日: 2012年11月28日 ページ情報: 英文 78 Pages
概要

当レポートでは、化学療法誘発性悪心嘔吐(CINV)パイプライン薬の市場普及と売上の促進因子について分析し、現在の市場動向、アンメットニーズ、市場課題、および治療薬の機会などについて取り上げ、各パイプライン薬の現在の治験状況と将来の市場普及率予測、地域別の市場分析、主要企業のプロファイルをまとめ、概略下記の構成でお届けいたします。

第1章 序文

第2章 エグゼクティブサマリー・市場概要

  • 世界のCINV薬剤市場:製品別
  • 世界のCINV薬剤の特許プール予測:薬剤別

第3章 CINV市場分析

  • 概要
  • CINV:現在利用可能な薬剤治療
  • CINV:パイプライン製品
  • CINV市場におけるアンメットニーズ
  • CINVパイプライン薬剤の治験詳細

第4章 CINVパイプライン薬剤市場の分析

  • CINV市場規模&機会の予測
  • パイプラインCINV薬剤売上の影響因子
  • CINVパイプライン薬剤の売上予測
  • CINVパイプライン薬剤のSWOT分析
  • パイプライン薬剤の全体的なライセンス合意

第5章 CINVパイプライン薬剤市場:地域別

  • 北米のCINVパイプライン薬剤市場
  • 欧州のCINVパイプライン薬剤市場

第6章 競合情勢

第7章 企業プロファイル

  • HELSINN HOLDING S.A.
    • 企業概要
    • 財務概要
    • 事業戦略
    • 近年の発展
  • CK INC.
  • TESARO INC.
  • AP PHARMA INC.

図表リスト

目次

This report is an effort to identify factors, which will be the driving force behind the market penetration and corresponding sales of the pipeline chemotherapy-induced nausea and vomiting (CINV) drugs, namely the combination drug netupitant - palonosetron FDC (fixed-dose combination), APF530 and rolapitant, in the next seven years. The report provides extensive analysis of APF530, rolapitant and netupitant - palonosetron (netu-palo) FDC, current market trends, unmet needs and challenges faced by the CINV market and opportunities for these drugs. The report has segregated the pipeline drugs in terms of estimated sales, patient pool and geography. The study presents a comprehensive assessment of the current clinical trials status and estimated future market penetration of each of these drugs in the CINV market and covers the following content as well:

  • Trends and forecast analysis for two prominent geographic markets, namely North America and Europe. Pipeline drug analysis of Asia and RoW (rest of the world) regions are not included in this study as it is assumed that the CINV pipeline drugs would be launched in these regions by 2018 and in the years ahead and so does not come under the scope of the forecast period of this report
  • Recent developments of major players and strategies followed by them for gaining competitive advantage
  • Profiles of major market participants for better understanding of their contributions

Table of Contents

CHAPTER 1 - PREFACE

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. LIST OF ACRONYMS
  • 1.4. SALES ASSUMPTIONS

CHAPTER 2 - EXECUTIVE SUMMARY AND MARKET OVERVIEW

  • 2.1. GLOBAL CINV DRUGS MARKET, BY PRODUCT, 2011 - 2018 (USD MILLION)
  • 2.2. GLOBAL CINV DRUGS ESTIMATED PATIENT POOL, BY DRUGS, 2009 - 2018

CHAPTER 3 - CINV MARKET ANALYSIS

  • 3.1. OVERVIEW
    • 3.1.1. AETIOLOGY/CAUSES FOR CINV
    • 3.1.2. MULTIPLE SYSTEMS INVOLVED IN THE PATHOGENESIS OF CINV
  • 3.2. CINV - CURRENT DRUG TREATMENTS AVAILABLE
    • 3.2.1. ANTICIPATORY N/V
    • 3.2.2. ACUTE-ONSET CINV
      • 3.2.2.1. Highly Emetogenic Chemotherapy
      • 3.2.2.2. Moderately Emetogenic Chemotherapy
      • 3.2.2.3. Low Emetogenic Chemotherapy
      • 3.2.2.4. Minimally Emetogenic Chemotherapy
    • 3.2.3. DELAYED-ONSET CINV
      • 3.2.3.1. Highly Emetogenic Chemotherapy
      • 3.2.3.2. Moderately Emetogenic Chemotherapy
  • 3.3. CINV - PIPELINE PRODUCTS
    • 3.3.1. APF530 (LONG-ACTING GRANISETRON - 5-HT3RA)
      • 3.3.1.1. Efficacy Results of APF530 MEC Phase III Study
      • 3.3.1.2. Efficacy Results of APF530 HEC Phase III Study
    • 3.3.2. ROLAPITANT (NK-1-RA)
      • Chemical structure of rolapitant
    • 3.3.3. NETUPITANT-PALONOSETRON FDC
      • 3.3.3.1. Introduction
      • 3.3.3.2. Mechanism of Action
      • Chemical structure of netupitant
  • 3.4. UNMET NEEDS IN THE CINV MARKET
  • 3.5. CLINICAL TRIAL DETAILS FOR CINV PIPELINE DRUGS
    • 3.5.1. APF530
      • 3.5.1.1. Clinical Trial: ID- NCT00343460
    • 3.5.2. ROLAPITANT
      • 3.5.2.1. Clinical Trial: ID - NCT01500226
      • 3.5.2.2. Clinical Trial: ID - NCT01500213
      • 3.5.2.3. Clinical Trial: ID - NCT01499849
    • 3.5.3. NETUPITANT-PALONOSETRON FDC
      • 3.5.3.1. Clinical Trial: ID - NCT01376297
      • 3.5.3.2. Clinical Trial: ID - NCT01339260

CHAPTER 4 - CINV PIPELINE DRUGS MARKET ANALYSIS

  • 4.1. CINV MARKET SIZE & OPPORTUNITY SCENARIO
    • 4.1.1. GLOBAL CINV PATIENT POOL, 2011 - 2018 (MILLION)
    • 4.1.2. GLOBAL CINV PATIENT POOL, BY DRUG TYPE, 2011 - 2018
    • 4.1.3. GLOBAL CINV PATIENT POOL, BY GEOGRAPHY, 2011 - 2018
    • 4.1.4. GLOBAL CINV MARKET, 2011 - 2018 (USD MILLION)
    • 4.1.5. GLOBAL CINV MARKET, BY GEOGRAPHY, 2011 - 2018 (USD MILLION)
  • 4.2. FACTORS INFLUENTIAL TO THE SALES OF PIPELINE CINV DRUGS
  • 4.3. SALES PROJECTION OF CINV PIPELINE DRUGS
    • 4.3.1. CINV PATIENT POOL ESTIMATE
      • 4.3.1.1. Global CINV Drugs - Target Patient Pool, 2009 - 2018
      • 4.3.1.2. Global CINV Drugs Market, 2011 - 2018 (USD million)
    • 4.3.2. NETUPITANT-PALONOSETRON FDC - SALES FORECAST
      • 4.3.2.1. Global Netupitant-Palonosetron FDC - Sales Projection (USD Million)
    • 4.3.3. ROLAPITANT - SALES FORECAST
      • 4.3.3.1. Global Rolapitant - Sales Projection (USD Million)
    • 4.3.4. APF530 - SALES FORECAST
      • 4.3.4.1. Global APF530 - Sales Projection (USD Million)
  • 4.4. SWOT ANALYSIS FOR CINV PIPELINE DRUGS
    • 4.4.1. NETUPITANT-PALONOSETRON FDC
      • 4.4.1.1. Netupitant - palonosetron FDC - Strength
      • 4.4.1.2. Netupitant - palonosetron FDC - Weakness
      • 4.4.1.3. Netupitant - palonosetron FDC - Opportunity
      • 4.4.1.4. Netupitant - palonosetron FDC - Threat
    • 4.4.2. ROLAPITANT
      • 4.4.2.1. Rolapitant - Strength
      • 4.4.2.2. Rolapitant - Weakness
      • 4.4.2.3. Rolapitant - Opportunity
      • 4.4.2.4. Rolapitant - Threat
    • 4.4.3. APF530
      • 4.4.3.1. APF530 - Strength
      • 4.4.3.2. APF530 - Weakness
      • 4.4.3.3. APF530 - Opportunity
      • 4.4.3.4. APF530 - Threat
  • 4.5. OVERALL LICENSE AGREEMENT FOR PIPELINE DRUGS
    • 4.5.1. NETUPITANT - PALONOSETRON FDC
      • 4.5.1.1. Global
      • 4.5.1.2. United States
      • 4.5.1.3. UK & Ireland
      • 4.5.1.4. Japan
      • 4.5.1.5. Australia
      • 4.5.1.6. Europe
      • 4.5.1.7. South Korea
    • 4.5.2. ROLAPITANT
    • 4.5.3. APF530

CHAPTER 5 - CINV PIPELINE DRUGS MARKET, BY GEOGRAPHY

  • 5.1. NORTH AMERICA CINV PIPELINE DRUGS MARKET, 2011 - 2018
    • 5.1.1. NORTH AMERICA CINV ESTIMATED PATIENT POOL, 2013 - 2018 (THOUSANDS)
    • 5.1.2. NORTH AMERICA CINV PIPELINE DRUGS MARKET, 2013 - 2018 (USD MILLION)
  • 5.2. EUROPE CINV PIPELINE DRUGS MARKET, 2011 - 2018
    • 5.2.1. EUROPE CINV ESTIMATED PATIENT POOL, 2014 - 2018 (THOUSANDS)
    • 5.2.2. EUROPE CINV PIPELINE DRUGS MARKET, 2014 - 2018 (USD MILLION)

CHAPTER 6 - COMPETITIVE LANDSCAPE

CHAPTER 7 - COMPANY PROFILES

  • 7.1. HELSINN HOLDING S.A.
    • 7.1.1. COMPANY OVERVIEW
    • 7.1.2. FINANCIAL OVERVIEW
      • 7.1.2.1. Helsinn Group's total assets, 2007 - 2011 (USD Million)
        • 7.1.2.1.1. Helsinn group total assets, 2007 - 2011 (USD million) (conversion rate: 1 Euro = 1.2744 USD)
      • 7.1.2.2. Helsinn's net turnover from netupitant - palonosetron FDC, 2010 - 2011 (USD Million)
        • 7.1.2.2.1. Helsinn's net turnover from netupitant - palonosetron fdc, 2010 - 2011 (USD million) (conversion rate: 1 Euro = 1.2744 USD)
      • 7.1.2.3. Helsinn Group's net turnover by products, 2011 (%)
        • 7.1.2.3.1. Helsinn Group's net turnover by products, 2011 (%)
      • 7.1.2.4. Helsinn Group's net turnover by business divisions, 2011 (USD Million)
      • 7.1.2.5. Comparative analysis of Helsinn Group's net turnover by geography, 2011 & 2012 (%)
    • 7.1.3. BUSINESS STRATEGIES
      • 7.1.3.1. Research and Development Initiatives
      • 7.1.3.2. Five year Vision
      • 7.1.3.3. Investing in new and emerging markets
      • 7.1.3.4. Strategic Alliances
      • 7.1.3.5. 4Ps and working towards developing a Quality of Life Company
      • 7.1.3.6. Efficient Business Model
    • 7.1.4. RECENT DEVELOPMENTS
  • 7.2. MERCK INC.
    • 7.2.1. COMPANY OVERVIEW
      • 7.2.1.1. Merck's total revenue by business segment, 2007 - 2011 (USD MILLION)
    • 7.2.2. BUSINESS STRATEGIES
      • 7.2.2.1. Corporate Social Responsibility
      • 7.2.2.2. R&D Initiatives
      • 7.2.2.3. Strategic alliances and out licensing
    • 7.2.3. PRODUCT PORTFOLIO
    • 7.2.4. RECENT DEVELOPMENTS
  • 7.3. TESARO INC.
    • 7.3.1. COMPANY OVERVIEW
    • 7.3.2. STRATEGIC OVERVIEW
    • 7.3.3. FINANCIAL OVERVIEW
    • 7.3.4. SWOT ANALYSIS
    • 7.3.5. RECENT DEVELOPMENT
  • 7.4. AP PHARMA INC.
    • 7.4.1. COMPANY OVERVIEW
    • 7.4.2. FINANCIAL OVERVIEW
    • 7.4.3. BUSINESS STRATEGY
    • 7.4.4 RECENT DEVELOPMENTS

LIST OF FIGURES

  • FIG. 1: GLOBAL CINV ESTIMATED PATIENT POOL, BY DRUGS, 2009-2018
  • FIG. 2: PATHOGENESIS OF CINV
  • FIG. 3: PATIENTS RECEIVING MEC
  • FIG. 4: PATIENTS RECEIVING HEC
  • FIG. 5: CHEMICAL SRUCTURE OF ROLAPITANT
  • FIG. 6: CHEMICAL SRUCTURE OF NETUPITANT
  • FIG. 7: GLOBAL CINV PATIENT POOL, 2011 - 2018 (MILLION)
  • FIG. 8: GLOBAL CINV MARKET 2011 - 2018 (USD MILLION)
  • FIG. 9: GLOBAL CINV ESTIMATED PATIENT POOL, BY DRUGS, 2009-2018
  • FIG. 10: GLOBAL NETUPITANT-PALONOSETRON FDC SALES PROJECTION, 2014 - 2018 (USD MILLION)
  • FIG. 11: GLOBAL ROLAPITANT SALES PROJECTION, 2014 - 2018 (USD MILLION)
  • FIG. 12: GLOBAL APF530 SALES PROJECTION, 2013 - 2018 (USD MILLION)
  • FIG. 13: HELSINN GROUP TOTAL ASSETS, 2007 - 2011 (USD MILLION) (CONVERSION RATE: 1 EURO = 1.2744 USD)
  • FIG. 14: HELSINN'S NET TURNOVER FROM NETUPITANT - PALONOSETRON FDC, 2010 - 2011 (USD MILLION) (CONVERSION RATE: 1 EURO = 1.2744 USD)
  • FIG. 15: HELSINN GROUP'S NET TURNOVER BY PRODUCTS, 2011 (%)
  • FIG. 16: HELSINN GROUP'S NET TURNOVER BY BUSINESS DIVISIONS, 2011 (USD MILLION)
  • FIG. 17: COMPARATIVE ANALYSIS OF HELSINN GROUP'S NET TURNOVER BY GEOGRAPHY, 2010 & 2011 (%)
  • FIG. 18: MERCK'S TOTAL REVENUE BY BUSINESS SEGMENT, 2007 - 2011 (USD MILLION)

LIST OF TABLES

  • TABLE 1: GLOBAL CINV DRUGS MARKET, BY PRODUCT, 2011-2018, (USD MILLION)
  • TABLE 2: CHEMOTHERAPY INDUCED NAUSEA AND VOMITING: CONDITIONS AND SYMPTOMS
  • TABLE 3: TREATMENT RECOMMENDATIONS FOR CINV
  • TABLE 4: OVERVIEW OF APF530 PHASE III EFFICACY WITH DIFFICULT CHEMO REGIMENS STUDY
  • TABLE 5: EVALUATION OF NETUPITANT-PALONOSETRON FDC
  • TABLE 6: CINV UNMET NEEDS
  • TABLE 7: DETAILS OF TRIAL ID - NCT00343460
  • TABLE 8: DETAILS OF TRIAL ID - NCT01500226
  • TABLE 9: DETAILS OF TRIAL ID - NCT01500213
  • TABLE 10: DETAILS OF TRIAL ID - NCT01499849
  • TABLE 11: DETAILS OF TRIAL ID - NCT01376297
  • TABLE 12: DETAILS OF TRIAL ID - NCT01339260
  • TABLE 13: GLOBAL CINV PATIENT POOL, BY DRUG TYPE, 2011 - 2018 (THOUSANDS)
  • TABLE 14: GLOBAL CINV PATIENT POOL, BY GEOGRAPHY, 2011 - 2018 (THOUSANDS)
  • TABLE 15: GLOBAL CINV MARKET, BY GEOGRAPHY, 2011 - 2018 (USD MILLION)
  • TABLE 16: GLOBAL CINV DRUGS MARKET, 2011 - 2018 (USD MILLION)
  • TABLE 17: NORTH AMERICA CINV ESTIMATED PATIENT POOL, 2013 - 2018 (THOUSANDS)
  • TABLE 18: NORTH AMERICA CINV PIPELINE DRUGS MARKET, 2013 - 2018 (USD MILLION)
  • TABLE 19: EUROPE CINV ESTIMATED PATIENT POOL, 2014 - 2018 (THOUSANDS)
  • TABLE 20: EUROPE CINV PIPELINE DRUGS MARKET, 2014 - 2018 (USD MILLION)
  • TABLE 21: PATENT STATUS OF ANTI-EMETIC DRUGS
  • TABLE 22: QUARTER THREE FINANCIAL RESULTS
Back to Top